Digoxin
Moderate
Database
Hypercalcaemia potentiates digoxin
Avoid hypercalcaemia; monitor
Source: Kimi deep-research + Cla
Drug reference
calcium dibasic phosphate
Calcium/phosphate salt supplement · Calcium supplement, Antacid
START
Elemental calcium 500 mg/day with food
TYPICAL MAX
Total intake ~2000–2500 mg elemental calcium/day
STOP IF
Hypercalcaemia, renal stones, or hyperphosphataemia (CKD)
WATCH
Serum/urinary calcium if high-dose; phosphate in CKD
CDSCO approvedATC A12AA04
KDIGO 2024 + manufacturer label
- ONSET
- 1w · repletion
- PEAK
- 2w · store effect
- t½
- 36s · homeostatic
- DURATION
- 1d · daily dosing
EXCRETION
Renal and faecal — homeostatically regulated
route + CYP
INTERACTIONS
—
none in our sources
PREGNANCY
Safe at recommended intakes in pregnancy.
FDA category + note
Mechanism
Provides elemental calcium and phosphate for bone mineralisation and to correct/prevent dietary calcium deficiency; dibasic calcium phosphate is a low-solubility calcium source.
Indications
Dietary calcium supplementation / deficiency preventionAdjunct in osteoporosis/osteomalaciaCalcium-deficient states
Dosing
- Adult
- Elemental calcium 500–1000 mg/day in divided doses with meals (per dietary gap and total intake target ~1000–1200 mg/day).
- Pediatric
- Per age-specific calcium requirement.
- Renal adjustment
- Caution in CKD (phosphate load / hyperphosphataemia); specialist guidance.
- Hepatic adjustment
- No specific adjustment.
- Geriatric
- Common in osteoporosis regimens; avoid excess (vascular/stone risk).
- Max dose
- Total elemental calcium intake ~2000–2500 mg/day (all sources)
Pharmacokinetics
Onset
Repletion over weeks
Peak effect
Serum calcium tightly regulated (not a peak drug)
Duration
Dosing-dependent
Half-life
Not applicable (physiologic homeostasis)
Bioavailability
~10–25% absorption (vitamin D / pH dependent)
Protein binding
~40% (albumin-bound serum calcium)
Metabolism
Not metabolised
Excretion
Renal and faecal (homeostatically regulated)
Contraindications
- Hypercalcaemia
- Severe hypercalciuria / calcium nephrolithiasis
- Hyperparathyroidism with hypercalcaemia
- Hypersensitivity
Side effects
Common
ConstipationBloatingFlatulenceNausea
Serious
- Hypercalcaemia
- Renal calculi
- Milk-alkali syndrome (excess intake)
Pregnancy & lactation
Pregnancy
Safe at recommended intakes in pregnancy.
Lactation
Compatible with breastfeeding at recommended intakes.
Drug interactions
Levothyroxine
Moderate
Database
Reduced absorption
Separate dosing widely
Source: Kimi deep-research + Cla
Tetracyclines
Moderate
Database
Calcium chelation
Separate by ≥2–4 h
Source: Kimi deep-research + Cla
Thiazide Diuretics
Moderate
Database
Reduced calcium excretion
Monitor serum calcium
Source: Kimi deep-research + Cla
Iron Salts
Mild
Database
Reduced iron absorption
Separate doses
Source: Kimi deep-research + Cla
Related guidelines
Iron deficiency anaemia in pregnancy
ICMR · Obstetrics & Gynaecology · 2022
Iron deficiency anaemia in adults
ICMR · Hematology · 2023
Iron deficiency anaemia in pregnancy
FOGSI · Obstetrics & Gynaecology · 2017
Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Ask House about calcium dibasic phosphate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20